GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Earnings per Share (Diluted)

KalVista Pharmaceuticals (STU:4XC1) Earnings per Share (Diluted) : €-3.33 (TTM As of Jul. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Earnings per Share (Diluted)?

KalVista Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jul. 2024 was €-0.80. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was €-3.33.

KalVista Pharmaceuticals's EPS (Basic) for the three months ended in Jul. 2024 was €-0.80. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jul. 2024 was €-3.33.

KalVista Pharmaceuticals's EPS without NRI for the three months ended in Jul. 2024 was €-0.81. Its EPS without NRI for the trailing twelve months (TTM) ended in Jul. 2024 was €-3.36.

During the past 3 years, the average EPS without NRIGrowth Rate was -12.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -22.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.20% per year.

During the past 13 years, KalVista Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 66.00% per year. The lowest was -131.00% per year. And the median was -16.80% per year.


KalVista Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for KalVista Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Earnings per Share (Diluted) Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.51 -2.02 -3.11 -3.04 -3.21

KalVista Pharmaceuticals Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.76 -0.77 -1.00 -0.80

Competitive Comparison of KalVista Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, KalVista Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's PE Ratio falls into.



KalVista Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

KalVista Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Apr. 2024 is calculated as

Diluted Earnings Per Share (A: Apr. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-118.032-0)/36.787
=-3.21

KalVista Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Jul. 2024 is calculated as

Diluted Earnings Per Share (Q: Jul. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-37.288-0)/46.233
=-0.81

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


KalVista Pharmaceuticals  (STU:4XC1) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


KalVista Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines